Allison B. Herman

Allison B. Herman

Auto-generated profile, based on publicly available information

Allison B. Herman

Laboratory of Cardiovascular Science (D.T., T.R.R., A.N.O., S.M.R., C.H.-S., A.B.H.), National Institute on Aging (NIA) Intramural Research Program (IRP), National Institutes of Health (NIH), Baltimore, MD

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
AHAllison B. Herman
Allison B. Herman
KGKatarína Grešová
Katarína Grešová
MMManolis Maragkakis
Manolis Maragkakis
MAMichael Autieri
Michael Autieri
Vascular smooth muscle cells (VSMCs) modulate their phenotype from a quiescent, contractile cell to a dedifferentiated, synthetic fibroproliferative cell in response to injury and cardiovascular risk factors. Senescence is a recognized phenotypically distinct cellular state characterized by cell cycle arrest and activation of the p16 and p53 damage response pathway and expression of the senescence-associated secretory phenotype. Low levels of senescence in healthy arteries contribute to vascular homeostasis by ensuring that only healthy VSMCs compose the artery, but they are not intended to be a persistent cellular component of the artery. However, when discussing VSMC phenotype modulation into foam-like cells, macrophages, mesenchymal cells, fibroblasts, adipocytes, and other VSMC-like cells, senescence is rarely included. This raises an intriguing question: can senescence be recognized as a phenotypic state of VSMCs? As understanding SMC phenotypic switching is crucial for developing therapies that can prevent and treat cardiovascular diseases, so is understanding mechanisms of senescence, and targeting the mechanisms that regulate this modulation could be a promising approach for managing conditions such as atherosclerosis, arterial calcification, and aortic aneurysms. This review aims to summarize recent findings about the molecular mechanisms of VSMC senescence and compare similarities and contrasts with the mechanisms known to regulate VSMC phenotype plasticity. Comparison of transcriptomic databases compelled us to also raise the interesting question: if VSMC can regain their contractile phenotype, can they also be coaxed to exit the senescent state and return to the contractile VSMC phenotype? We posit that senescent VSMCs may not be an end point but rather an intermediate or inflection point in VSMC cell fate decision.

18 August 2025 in bioRxiv
Verified
Preprint
Open access
SMSophia A. Mahoney
Sophia A. Mahoney
KMKrystyna Mazan-Mamczarz
Krystyna Mazan-Mamczarz
DTDimitrios Tsitsipatis
Dimitrios Tsitsipatis
NVNicholas S. VanDongen
Nicholas S. VanDongen
CHCharnae’ Henry-Smith
Charnae’ Henry-Smith
ZCZachary S Clayton
Zachary S Clayton
Background: Advancing age is the strongest risk factor for cardiovascular diseases (CVDs), primarily due to progressive vascular endothelial dysfunction. Cellular senescence and the senescence-associated secretory phenotype (SASP) contribute to age-related endothelial dysfunction by promoting mitochondrial oxidative stress and inflammation, which reduce nitric oxide (NO) bioavailability. However, the molecular changes in senescent endothelial cells and their role in endothelial dysfunction with aging remain incompletely unclear. As such, in this study we sought to identify the endothelial cell senescence-related signalling pathways, endothelial-derived SASP factors, and their impact on endothelial function with aging. Methods: Single-cell transcriptomics was performed on aortas from young (6 months) and old (27 months) mice with and without in vivo senolytic treatment with fisetin (100 mg/kg/day administered in an intermittent dosing paradigm) to characterize endothelial cell senescence and transcript expression changes. Circulating levels of SASP factors were measured to validate transcriptional changes. Plasma exposure and protein addition and inhibiton experiments were conducted in isolated mouse arteries and cultured human endothelial cells to determine the causal role of the circulating SASP milieu and specific SASP factors in mediating endothelial dysfunction and underlying mechanisms-of-action. Results: Senescent endothelial cells exhibited elevated expression of SASP factors, particularly Cxcl12 , which was reversed by fisetin supplementation, with responses also reflected in circulating CXCL12 concentrations. Plasma from old mice impaired endothelial function by inducing vascular cell senescence, reducing NO, increasing mitochondrial oxidative stress, and promoting endothelial-to-mesenchymal transition—effects partially driven by CXCL12 and prevented by fisetin. Conclusions: These results identify the SASP and CXCL12 as drivers of age-related endothelial dysfunction and establish mechanisms of senolytic intervention with fisetin supplementation. NOVELTY AND SIGNFICANCE: What is known?: Advancing age is the primary risk factor for cardiovascular disease, in part due to progressive endothelial dysfunction. Cellular senescence contributes to age-related endothelial impairment through the secretion of a pro-inflammatory milieu known as the senescence-associated secretory phenotype (SASP), which can affect neighboring cells and tissue function. Senolytic compounds selectively eliminate senescent cells and improve vascular function in preclinical models of aging. What new information does this article contribute?: Endothelial cells are highly susceptible to senescence with aging in vivo and are selectively cleared by senolytic treatment with the natural compound fisetin. Single-cell transcriptomic profiling identifies CXCL12 as the most highly upregulated SASP factor in senescent endothelial cells and in circulation with aging, both of which are reversed by senolytic treatment with fisetin. We identify a specific circulating SASP factor, CXCL12, as a partial mediator of endothelial dysfunction by inducing mitochondrial oxidative stress, impairing nitric oxide bioavailability, and promoting endothelial-to-mesenchymal transition (Endo, which is restored by senolytic treatment with fisetin. Summary: This study provides novel mechanistic insight into how senescent endothelial cells and their secretory products—particularily CXCL12—contribute to age-related endothelial dysfunction. It further demonstrates that senolytic treatment with fisetin reverses these effects, highlighting a promising translational strategy for targeting vascular aging and preserving endothelial health. GRAPHICAL

1 May 2026 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
DTDimitrios Tsitsipatis
Dimitrios Tsitsipatis
TRTatiana Rodriguez Rivera
Tatiana Rodriguez Rivera
MKMary Kaila
Mary Kaila
AOAda N. Okereke
Ada N. Okereke
AGAditi Gupta
Aditi Gupta
AHAllison B. Herman
Allison B. Herman
BACKGROUND: This study aimed to determine the effect of senescent vascular smooth muscle cells (VSMCs) on foam cell formation and macrophage phagocytic activity in atherosclerotic conditions. METHODS: We measured the capacity of senescent VSMCs for scavenging oxLDL (oxidized low-density lipoprotein), which was impaired in senescent cells compared with proliferating and quiescent cells. Next, we obtained human peripheral blood monocytes from people >60 years old and differentiated them into macrophages using GM-CSF (granulocyte-macrophage colony-stimulating factor). We treated the macrophages with conditioned media derived from proliferating, quiescent, and senescent VSMCs and measured oxLDL uptake, phagocytosis, and efferocytosis. RESULTS: The results demonstrated that macrophages treated with senescent VSMC conditioned media experienced impaired oxLDL uptake, phagocytic activity, and reduced ability to clear senescent cells. Treatment of senescent VSMCs with senomorphic drugs before conditioned media transfer restored macrophage functions, confirming that the SASP (senescence-associated secretory phenotype) is critical for impairing macrophages during atherosclerotic conditions. CONCLUSIONS: Our results suggest that the SASP derived from senescent VSMCs prevents foam cell formation and disrupts the homeostatic function of macrophages in atherosclerosis. By suppressing macrophage function, senescent cells seem to evade immune clearance and accumulate, further propagating disease development.